Drugs / Jinshuibao
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04349683 | Apr 2020 → Aug 2021 | chronic kidney disease, glomerulonephritis | Jemincare | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jinshuibao | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04349683 ↗ |
| Known as | Jinshuibao capsule | “Jinshuibao capsule, which is composed of fermented cordyceps sinensis powder (Cs-4) , has shown therapeutic effects in chronic kidney disease (CKD)” NCT04349683 ↗ |